SOMAVAC® Medical Solutions, Inc. is a MedTech company developing and pioneering new technology platforms to mitigate surgical complications, improve treatment protocols, and reduce the overall cost of healthcare. Our platforms are led by our patented SOMAVAC® Deep Tissue Negative Pressure Therapy which is the first powered negative pressure therapy device cleared for seroma prophylaxis. For patients undergoing breast reconstruction and/or mastectomies, negative pressure delivered by SOMAVAC® removes fluid as it is produced, obliterates dead space, and holds tissues together which have been shown to prevent seromas. Seromas can lead to surgical complications like surgical site infections, wound dehiscence, etc. SOMAVAC® is FDA cleared for seroma prophylaxis. For more complex procedures, our recent patent combines SOMAVAC®'s Deep Tissue Negative Pressure Therapy (dtNPT) with the added benefit of closed-incision negative pressure wound therapy (ciNPWT). This patent is for the only comprehensive device that allows surgeons to optimize surgical outcomes with negative pressure therapy both inside the surgical site and outside the incision which creates a new medical device category and deepens the penetration of the $1.1B immediate US Market.
